Akcea Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akcea Therapeutics, Inc.
After being selected as an awardee of J&J’s Innovation QuickFire Challenge On Neuroscience in June, Korean bioventure BIORCHESTRA has been attracting attention from the global neuroscience community. CEO Branden Ryu talks to Scrip what makes its technology unique and how it aims to meet major unmet needs in RNA therapeutics and neurodegenerative disorders.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.
- Antisense, Oligonucleotides